硬脂酰胺MIPA | 35627-96-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 硬脂酰胺MIPA
• 英文名称: N-(2-hydroxy-propyl)-stearamide
• 英文别名: Stearinsaeure-(2-hydroxy-propylamid)；N-(2-Hydroxy-propyl)-stearamid；N-(2-Hydroxy-propyl)-stearinamid；stearic acid monoisopropanolamide；N-(2-Hydroxypropyl)stearamide；N-(2-hydroxypropyl)octadecanamide
• CAS: 35627-96-4
• 化学式: C₂₁H₄₃NO₂
• 分子量: 341.578
• InChiKey: QCTVGFNUKWXQNN-UHFFFAOYSA-N

物化性质

• 沸点：
  493.8±28.0 °C(Predicted)
• 密度：
  0.901±0.06 g/cm3(Predicted)
• LogP：
  7.169 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  24
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090

反应信息

• 作为产物：
  描述：

  硬酯酸甲酯C18 、 异丙醇胺 、 sodium methylate 生成 硬脂酰胺MIPA
  参考文献：
  名称：

  BEN-BASSAT, ALBERT A.;WASSERMAN, TAMAR, J. LIQUID CHROMATOGR., 10,(1987) N 13, 2939-2950

  摘要：

  DOI：

文献信息

• [EN] QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO<br/>[FR] DÉRIVÉS DE QUINAZOLINE, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2013181135A1

  公开（公告）日：2013-12-05

  The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase.

  该披露涉及喹唑啉衍生物、组合物以及相关方法。在某些实施例中，该披露涉及NADPH-氧化酶（Nox酶）和/或髓过氧化物酶的抑制剂。
• Water-Soluble Derivatives and Prodrugs of Acacetin and Methods of Making and Using Thereof
  申请人：Shanghai Institute of Pharmaceutical Industry

  公开号：US20150218193A1

  公开（公告）日：2015-08-06

  Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

  水溶性阿克塞丁衍生物和/或前药在本发明中有所描述。这些化合物可用作针对由缺血-再灌注引起的心肌梗死的护心剂。在一个实施例中，这些化合物用于治疗缺血性心脏病。在优选的实施例中，这些化合物用于治疗和/或预防人类的心肌梗死。
• [EN] NUCLEOSIDE PRODRUGS AND USES RELATED THERETO<br/>[FR] PROMÉDICAMENTS NUCLÉOSIDIQUES ET LEURS UTILISATIONS
  申请人：UNIV EMORY

  公开号：WO2021035214A1

  公开（公告）日：2021-02-25

  Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω -oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

  揭示了具有改善代谢稳定性和口服生物利用度的非环核苷前药。一般来说，这些前药是非环核苷膦酸酯的衍生物，含有类似脂质的基团，可以增加口服吸收并在肝脏和血浆中提高稳定性。最好，类似脂质的基团可以抵抗酶介导的ω-氧化，例如细胞色素P450酶催化的ω-氧化。还揭示了非环核苷前药的药物配方。这些非环核苷前药及其药物配方可用于治疗病毒感染，如HIV感染，和/或病毒相关癌症，如HPV相关癌症。
• [EN] TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS CIBLÉS, PARTICULES ET PRÉPARATIONS ASSOCIÉES
  申请人：TARVEDA THERAPEUTICS INC

  公开号：WO2017003940A1

  公开（公告）日：2017-01-05

  Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as maytansinoid attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided.

  纳米颗粒和微粒，以及其中含有活性药物的共轭物，例如连接到靶向基团（如生长抑素受体结合基团）的马替南素的共轭物已经被设计出来。这种纳米颗粒和微粒可以提供改善活性药物的时间空间传递和/或改善生物分布。提供了制备这些共轭物、颗粒和制剂的方法。提供了将这些制剂用于需要的受试者的方法。
• [EN] PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR EP2 DES PROSTAGLANDINES, DÉRIVÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2015167825A1

  公开（公告）日：2015-11-05

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  该披露涉及前列腺素受体EP2拮抗剂，衍生物，组合物以及相关方法。在某些实施例中，该披露涉及治疗或预防EP2受体激活在生理作用中起作用的疾病和疾病的方法，例如但不限于脑损伤，炎症性疾病，癫痫后的神经炎症，疼痛，子宫内膜异位症，癌症，类风湿性关节炎，皮肤炎症，血管炎症，结肠炎和神经系统疾病，通过向需要的受试者给予包含本文所披露的化合物的药物组合物进行治疗。